On 2 September, Brazil's Anvisa suspended two Unilever production lines making OMO and Comfort: the trigger was gaps in the company's own water-monitoring and batch-release records, not a single contaminated unit

What the 2 September suspension actually does

Anvisa's Good Manufacturing Practices rules for saneantes, cleaning and sanitizing products regulated as a distinct category under Brazilian health law, are set out in Resolução RDC No. 47/2013. That regulation requires a manufacturer to control, and document, the factors that can affect a product's quality at every stage: raw-material intake, in-process checks, pre-release testing, and how deviations are investigated once they are found. Resolution RE No. 3,443/2026 does not accuse Unilever of breaching a numeric safety limit or of shipping a contaminated batch. It accuses the Vinhedo plant of failing to run that documented control system correctly on two of its production lines: the joint inspection team reported that controls performed during manufacturing and before releasing a batch to market were inadequate, that monitoring of the water used in production had gaps, and that when Unilever's own quality staff identified a problem, the investigation and correction of it fell short of what RDC 47/2013 requires. Anvisa's preventive measure suspends new manufacturing on the two affected lines only, not the wider Vinhedo site and not the products already sold: it is explicit that the goal is to stop new batches being made under the identified gaps until they are corrected, not to withdraw units already in stores or in consumers' homes. Unilever said, in a statement reported alongside the resolution's publication, that the affected lines were temporarily suspended for implementation of required operational improvements, that corrective work had already begun, and that every other line at the plant kept operating normally. Neither Anvisa nor Unilever has published a date for when manufacturing on the two lines can resume; under RDC 47/2013 that depends on the company completing the corrections and, typically, a follow-up inspection confirming them.

The numbers behind the suspension

One number is how many of Unilever's own production lines the order actually reaches. One is how many household brands sit on those two lines. The third shows this was not a one-off: Anvisa had already run this kind of inspection on Brazil's cleaning-product makers several times this year.

The real subject: a shutdown without a single contaminated batch

Most coverage of this case in Brazil led with the same reassurance Anvisa itself put first: no contamination, no recall, existing stock still safe to use. That framing is accurate, and it is also why the case deserves more attention than an ordinary product recall gets. A safety recall starts with a positive test result, a specific defect found in a specific batch, and the compliance question that follows is which units contain it. This suspension started somewhere else entirely: an inspection of Unilever's own records. The three agencies did not report finding a contaminated batch; they reported that the systems meant to catch a contaminated batch before it ever leaves the plant, in-process controls, pre-release checks, water-quality monitoring, and the follow-up on problems the company's own staff had already flagged, were not being run and documented the way RDC 47/2013 requires. That is a different kind of finding, and it carries a different kind of consequence: Anvisa did not need to prove a single unit was unsafe to justify halting new production, because the regulation does not condition a Brazilian saneante manufacturer's right to keep producing on whether its last shipped batch tested clean. It conditions that right on the manufacturer being able to show, batch by batch and on demand, that its own quality-control process actually ran as documented. A plant can ship years of clean product while that underlying documentation has gaps, and the day an inspector finds the gap, not a contaminated unit, is the day production stops.

Why it matters for brands

The direct exposure sits with any manufacturer of saneantes, cosmetics, food or medical products running its own factory in Brazil, since RDC 47/2013 and its sister Good Manufacturing Practices regulations apply the same documented-process standard regardless of company size or brand recognition; this case shows Anvisa will suspend a named line at a multinational's plant on that basis alone. Three groups beyond Unilever should read the finding closely. First, any consumer-goods company running more than one production line at a shared Brazilian facility: Anvisa's order reached two specific lines, not the whole site, which means a compliance team has to be able to show, line by line, which of its own quality-control records are complete and which are not, rather than treating a plant's GMP status as a single pass or fail. Second, any brand that outsources manufacturing to a Brazilian co-packer for saneantes, cosmetics or food: the documented-process standard this case turned on, water-monitoring logs, in-process and pre-release sign-offs, investigation records for self-identified deviations, belongs to the manufacturing site, and a brand cannot rely on its own finished-product testing to stand in for a co-packer's recordkeeping gap. Third, this suspension followed Anvisa's seventh Good Manufacturing Practices inspection of a sanitizing-product maker in 2026, four of which had already targeted Brazil's largest companies in the sector: a brand operating in this category should treat its own documentation, not only its finished-product test results, as the thing an inspector is most likely to examine next.

Two ways to read the Unilever suspension

Frequently asked questions